Quarterly ResultMay 7, 2026, 07:37 AM
Zura Bio Q1 Net Loss $(24.2)M; Cash $225.6M after Equity Offering
AI Summary
Zura Bio Ltd. reported a net loss of $(24.2) million for the first quarter of 2026, an increase from $(17.4) million in the same period last year, with total operating expenses rising to $25.5 million. Despite ongoing losses and an accumulated deficit of $(248.8) million, the company significantly bolstered its liquidity. Cash and cash equivalents surged to $225.6 million as of March 31, 2026, primarily due to net proceeds of approximately $134.6 million from a February 2026 equity offering.
Key Highlights
- Net loss for Q1 2026 was $(24.2) million, compared to $(17.4) million for Q1 2025.
- Cash and cash equivalents increased to $225.6 million as of March 31, 2026, from $109.4 million at December 31, 2025.
- Total operating expenses rose to $25.5 million in Q1 2026 from $19.3 million in Q1 2025.
- Accumulated deficit reached $(248.8) million as of March 31, 2026.
- Net cash used in operating activities was $(18.9) million for Q1 2026.
- The February 2026 Equity Offering generated approximately $134.6 million in net proceeds.
- The offering included 21.2 million Class A Ordinary Shares and 1.8 million Pre-funded Warrants.
- The company expects to no longer be an emerging growth company effective December 31, 2026.